The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,951.00
Ask: 1,953.00
Change: -1.00 (-0.05%)
Spread: 2.00 (0.103%)
Open: 1,942.00
High: 1,958.00
Low: 1,938.00
Prev. Close: 1,959.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

27 Jun 2016 07:01

RNS Number : 2760C
Hikma Pharmaceuticals Plc
27 June 2016
 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

SAID DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

150,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.06%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£22.00p

14.

Date and place of transaction

 

24 JUNE 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

13,313,161 (5.56%) COMPRISING:

 

DIRECTLY, INCLUDING CONNECTED PERSONS: 745,383 (0.31%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 12,567,778 (5.25%)

16.

Date issuer informed of transaction

 

 

24 JUNE 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 27 June 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MAZEN DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

150,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.06%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£22.00p

14.

Date and place of transaction

 

24 JUNE 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

7,279,931 (3.04%) COMPRISING:

 

DIRECTLY: 952,965 (0.40%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 6,326,966 (2.64%)

16.

Date issuer informed of transaction

 

 

24 JUNE 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 27 June 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MOHAMMED 'ALI' AL-HUSRY

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 150,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

150,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.06%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£22.00p

14.

Date and place of transaction

 

24 JUNE 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

5,814,166 (2.43%) UNDER DYKB LIMITED COMPRISING:

 

DIRECTLY: 1,162,811 (0.49%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 4,651,355 (1.94%)

16.

Date issuer informed of transaction

 

 

24 JUNE 2016

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 27 June 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBSGDLUUDBGLU
Date   Source Headline
16th May 20133:32 pmRNSResult of AGM
16th May 20137:00 amRNSInterim Management Statement
10th May 20133:05 pmRNSDirector/PDMR Shareholding
2nd May 20133:16 pmRNSDirector/PDMR Shareholding
23rd Apr 20133:32 pmRNSDirector/PDMR Shareholding
18th Apr 201310:29 amRNSDirector/PDMR Shareholding
17th Apr 20137:00 amRNSHikma update on global Injectables business
10th Apr 20132:35 pmRNSAnnual Financial Report
5th Apr 201311:03 amRNSAnnual Information Update
5th Apr 201311:00 amRNSBlocklisting Interim Review
5th Apr 201310:53 amRNSTotal Voting Rights
25th Mar 20132:42 pmRNSDirector/PDMR Shareholding
13th Mar 20137:00 amRNSPreliminary Results
1st Mar 201310:24 amRNSResponse to unsolicited enquiries
4th Feb 201310:29 amRNSHikma signs agreement with EffRx
21st Jan 201310:17 amRNSAdditional Listing
9th Jan 20137:00 amRNSAcquisition
3rd Jan 20133:55 pmRNSTotal Voting Rights
3rd Jan 20133:49 pmRNSNon Regulatory Announcement
27th Dec 20123:31 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSProduct Launch
27th Nov 20121:45 pmRNSBuilding Public Trust Awards - Highly Commended
12th Nov 20129:48 amRNSTotal Voting Rights
2nd Nov 20127:00 amRNSInterim Management Statement
1st Nov 201210:02 amRNSHolding(s) in Company
22nd Oct 201210:13 amRNSHikma & GP Pharm signs license & supply agreement
11th Oct 20121:00 pmRNSInjectables Analyst and Investor Day USA
10th Oct 201210:27 amRNSBlocklisting Interim Review
10th Oct 201210:06 amRNSTotal Voting Rights
4th Oct 20129:29 amRNSDividend Declaration
16th Aug 20127:00 amRNSHalf Yearly Report
8th Aug 201210:03 amRNSHolding(s) in Company
6th Jul 201212:24 pmRNSTotal Voting Rights
3rd Jul 20125:36 pmRNSHolding(s) in Company
29th Jun 201212:22 pmRNSDirector/PDMR Shareholding
25th Jun 201211:20 amRNSDirector/PDMR Shareholding
21st Jun 20123:04 pmRNSDirector/PDMR Shareholding
6th Jun 201211:34 amRNSTotal Voting Rights
18th May 201210:46 amRNSDirector/PDMR Shareholding
17th May 20123:27 pmRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
1st May 20123:50 pmRNSHolding(s) in Company
20th Apr 201212:50 pmRNSHolding(s) in Company
16th Apr 20129:57 amRNSAnnual Information Update
13th Apr 201211:39 amRNSAnnual Financial Report & AGM Notice
4th Apr 20124:15 pmRNSCompany Secretary Change
2nd Apr 20125:21 pmRNSTotal Voting Rights
2nd Apr 20125:14 pmRNSBlocklisting Interim Review
28th Mar 201211:12 amRNSDirector/PDMR Shareholding
19th Mar 20124:52 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.